A Short Review on Important Drugs Under Clinical Trial Against COVID-19

Author(s): Namita Misra*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 21 , Issue 13 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Coronavirus spreads from one to another person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. COVID-19 infected human symptoms are like pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. It was first notified in China dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures, everyone should follow the World Health Organization's advice guidelines on the management of humans infected with known or suspected infection with the SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same is in progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.

Keywords: COVID-19, pneumonia, URI, WHO, SARS-CoV-2.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 13
Year: 2021
Published on: 17 December, 2020
Page: [1666 - 1678]
Pages: 13
DOI: 10.2174/1389557521666201217145333
Price: $65

Article Metrics

PDF: 43